Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
about
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.A Palladium-Catalyzed Carbonylation Approach to Eight-Membered Lactam Derivatives with Antitumor Activity.Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance.Exploration of ligand binding modes towards the identification of compounds targeting HuR: a combined STD-NMR and Molecular Modelling approach
P2860
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
@en
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
@nl
type
label
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
@en
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
@nl
prefLabel
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
@en
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
@nl
P2093
P50
P356
P1476
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma
@en
P2093
Domenico Delia
Elisabetta Corna
Elisabetta Moroni
Vittoria Castiglioni
P304
P356
10.1021/MP4004578
P407
P50
P577
2013-11-27T00:00:00Z